Movement Alert|Genmab A/S Intraday Decline 4.09%, Earlier earnings and oncology trial catalysts lose momentum

Market Focus
Nov 12

On November 12, Genmab A/S fell 4.09% in Regular Trading, trading at $51.62/share, with Turnover of $66.8827 million.

The move followed a pullback after earlier catalysts had already driven a sharp re-rating, with trading momentum cooling around the company’s recent earnings beat and positive Petosemtamab phase 3 update.

Genmab A/S previously reported third-quarter EPS of $5.51, well above the $3.59 consensus estimate, while sales were $1.187 billion versus $1.194 billion expected, and it maintained full-year guidance. Separately, Petosemtamab plus pembrolizumab met both primary endpoints in the phase 3 LiGeR-HN1 study, reducing the risk of death by 50% in certain first-line head and neck cancer patients. Recent weakness appears tied to fading event-driven momentum after those gains were already reflected in the share price.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10